Suppr超能文献

非糜烂性胃食管反流病质子泵抑制剂治疗抵抗的特征。

Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.

机构信息

Center for Clinical Research, Hamamatsu University School of Medicine, Shizuoka Hamamatsu 431-3192, Japan.

出版信息

World J Gastroenterol. 2011 Apr 14;17(14):1858-65. doi: 10.3748/wjg.v17.i14.1858.

Abstract

AIM

To investigate whether potent acid inhibition is effective in non-erosive reflux disease (NERD) refractory to standard rabeprazole (RPZ) treatment.

METHODS

We treated 10 Japanese patients with NERD resistant to standard dosages of RPZ: 10 mg or 20 mg od, 20 mg bid, or 10 mg qid for 14 d. All patients completed a frequency scale for symptoms of gastroesophageal reflux disease questionnaire frequency scale for the symptoms of GERD (FSSG); and underwent 24 h pH monitoring on day 14.

RESULTS

With increased dosages and frequency of administration of RPZ, median intragastric pH significantly increased, and FSSG scores significantly decreased. With RPZ 10 mg qid, potent acid inhibition was attained throughout 24 h. However, five subjects were refractory to RPZ 10 mg qid, although the median intragastric pH in these subjects (6.6, range: 6.2-7.1) was similar to that in the remaining five responsive subjects (6.5, range: 5.3-7.3). With baseline RPZ 10 mg od, FSSG scores in responsive patients improved by > 30%, whereas there was no significant decrease in the resistant group.

CONCLUSION

NERD patients whose FSSG score fails to decrease by > 30% after treatment with RPZ 10 mg od for 14 d are refractory to higher dosage.

摘要

目的

研究强效抑酸治疗是否对标准剂量雷贝拉唑(RPZ)治疗无效的非糜烂性反流病(NERD)有效。

方法

我们治疗了 10 例对标准剂量 RPZ 耐药的日本 NERD 患者:10 毫克或 20 毫克,每日一次;20 毫克,每日两次;或 10 毫克,每日四次,共 14 天。所有患者均完成了胃食管反流病症状频率量表(FSSG)和 24 小时 pH 监测。

结果

随着 RPZ 剂量和给药频率的增加,胃内 pH 值中位数显著升高,FSSG 评分显著降低。RPZ 10 毫克,每日四次可实现 24 小时强效抑酸。然而,有 5 名患者对 RPZ 10 毫克,每日四次耐药,尽管这些患者的胃内 pH 值中位数(6.6,范围:6.2-7.1)与其余 5 名反应良好的患者相似(6.5,范围:5.3-7.3)。在基线时使用 RPZ 10 毫克,每日一次,反应良好的患者的 FSSG 评分改善了>30%,而耐药组则没有显著下降。

结论

在使用 RPZ 10 毫克,每日一次治疗 14 天后,FSSG 评分未降低>30%的 NERD 患者对更高剂量的 RPZ 耐药。

相似文献

1
Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.
World J Gastroenterol. 2011 Apr 14;17(14):1858-65. doi: 10.3748/wjg.v17.i14.1858.
3
Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
J Gastroenterol. 2012 Mar;47(3):284-92. doi: 10.1007/s00535-011-0488-5. Epub 2011 Nov 15.
5
Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
World J Gastroenterol. 2015 Apr 28;21(16):5023-31. doi: 10.3748/wjg.v21.i16.5023.
6
Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
Dig Endosc. 2012 Nov;24(6):407-11. doi: 10.1111/j.1443-1661.2012.01301.x. Epub 2012 Apr 8.
10
Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
J Gastroenterol Hepatol. 2013 Mar;28(3):479-87. doi: 10.1111/j.1440-1746.2012.07266.x.

引用本文的文献

1
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
J Gastroenterol. 2022 Apr;57(4):267-285. doi: 10.1007/s00535-022-01861-z. Epub 2022 Feb 28.
2
Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
Dig Dis Sci. 2017 Nov;62(11):3059-3068. doi: 10.1007/s10620-017-4743-3. Epub 2017 Sep 15.
4
Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
J Gastroenterol. 2016 Aug;51(8):751-67. doi: 10.1007/s00535-016-1227-8. Epub 2016 Jun 21.
6
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
Eur J Clin Pharmacol. 2014 Sep;70(9):1073-8. doi: 10.1007/s00228-014-1713-y. Epub 2014 Jul 6.
7
Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.
World J Gastroenterol. 2013 May 28;19(20):3124-9. doi: 10.3748/wjg.v19.i20.3124.

本文引用的文献

4
Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.
J Gastroenterol. 2008;43(9):670-8. doi: 10.1007/s00535-008-2214-5. Epub 2008 Sep 20.
6
Validity of endoscopic classification of nonerosive reflux disease.
J Gastroenterol. 2007 Jun;42(6):444-9. doi: 10.1007/s00535-007-2022-3. Epub 2007 Jun 29.
7
Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method.
J Gastroenterol Hepatol. 2007 Jul;22(7):1057-63. doi: 10.1111/j.1440-1746.2006.04546.x.
9
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Dig Dis Sci. 2007 Jul;52(7):1673-7. doi: 10.1007/s10620-006-9674-3. Epub 2007 Mar 24.
10
Functional dyspepsia and non-erosive reflux disease. A review.
Minerva Gastroenterol Dietol. 2006 Sep;52(3):261-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验